Generic Name and Formulations:
Trifluridine 1%; oph. soln; contains thimerosal.
Indications for VIROPTIC:
Primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex types 1 and 2.
Adults and Children:
<6yrs: not recommended. Do not exceed recommended dose. ≥6yrs: 1 drop every 2hrs while awake; max 9 drops/day. After reepithelialization, 1 drop every 4hrs for 7 days (at least 5 drops/day); max 21 days therapy. Reevaluate if no improvement in 7 days or incomplete reepithelialization in 14 days.
Glaucoma. Pregnancy (Cat.C). Nursing mothers.
Transient ocular burning or stinging, keratopathy, edema, irritation, keratitis sicca, hyperemia, increased intraocular pressure.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy